Clinical trials: PD-L1 Expression
Lung Neoplasms
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records.
- Trial name
- DeniLA (NCT07109154)
- Where
- 7 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Head and Neck Squamous Cell Carcinoma, Magnetic Resonance Imaging
Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy
The goal of this observational study is to explore the application of temporal diffusion spectroscopy MRI in head and neck squamous cell carcinoma (HNSCC).
- Conditions
- Head and Neck Squamous Cell Carcinoma, Magnetic Resonance Imaging, Neoadjuvant Therapy
- Trial name
- NCT05964595
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
B-cell Malignancies
Expression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by Flowcytometry
B-cell malignancies include a spectrum of cancers originating from abnormal B lymphocytes at different developmental stages (1) that affect the peripheral blood (PB), bone marrow (BM), and lymphatic system.
- Trial name
- NCT07515313
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Assiut University
Osteosarcoma
Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS
RATIONALE: Studying samples of tumor tissue from patients with advanced osteosarcoma refractory to chemotherapy in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to…
- Trial name
- CSSG-02 (NCT03997747)
- Testing
- cytology specimen
- Where
- 2 sites in China
- Volunteers
- 38 people
- Sponsor
- Peking University People's Hospital
Bladder Cancer
Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer
Non-muscle-invasive bladder cancer (NMIBC) has a high rate of recurrence (60 to 70%) and progression (20 to 30%) to muscle-invasive bladder cancer (MIBC).
- Trial name
- IMMUN VESSIE (NCT04726735)
- Testing
- Samples of bladder tissue
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Endometrial Cancer, Ovarian Cancer
Tumor Grade Determines PD-1/PDL-1 Expression
Endometrial carcinoma is the most common gynecologic cancer in the western world. Two types are usually described. Type I is the endometrioid and is usually estrogen dependent.
- Trial name
- NCT04528940
- Testing
- PD-1/PDL-1 staining
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- RWJ Barnabas Health at Jersey City Medical Center
Pancreatic Adenocarcinoma
Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma
Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor. In Egypt, the disease has traditionally been considered rare, but population in the East Nile Delta region exhibits an…
- Trial name
- NCT05228808
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Nasopharyngeal and Hypopharyngeal Carcinoma
Expression of Programmed Death Ligand-1 (PD-L1) in Nasopharyngeal and Hyypopharyngeal Carcinoma
Head and neck tumors comprise heterogeneous neoplasms that arise from surface epithelium of different anatomic subsites in head and neck region such as oral cavity, oropharynx, larynx and hypopharynx.
- Trial name
- NCT05595265
- Testing
- immunohistochemical
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with…
- Trial name
- NCT03092739
- Testing
- PD-L1 Immunocytochemistry (ICC), PD-L1 Immunohistochemistry (IHC)
- Where
- 8 sites in Czechia, Germany and 4 more
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Acute Lymphoblastic Leukemia in Pediatric
Expression of Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PDL-1) in Acute Lymphoblastic Leukemia in Pediatric
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy in the world. It is a malignant clonal proliferation of lymphoid progenitor cells, but most commonly of the B cell lineage (B ALL). .
- Trial name
- NCT05428111
- Testing
- flow cytometric immunophynotyping
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Progression, Survival
PD-L1 Expression in Advanced Osteosarcoma
The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment.
- Trial name
- NCT03582527
- Testing
- all study participants
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Urinary Bladder Neoplasm
SOX2 & PDL1 Expression on Urinary Bladder Carcinoma
Bladder carcinoma (BC) is the 13th leading cause of cancer mortality worldwide . In Egypt, BC is the third common malignant tumor.
- Trial name
- NCT05429710
- Volunteers
- 60 people
- Sponsor
- Sohag University